Skip to main content Skip to search Skip to main navigation
Question of the Week | GMP-Verlag

What is the difference between a correction and a corrective action?

While the correction pursues exclusively the elimination of the defect – as with the elimination of a symptom – a corrective action is concerned with the elimination of the cause of the defect identified in the root cause analysis. The goal of a correction is to comply with the requirement, while the goal of a corrective action is to prevent the recurrence of the specific defect.

[GMP Compliance Adviser, Chapter 1.F]

Would you Like to Discover More?

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The free demo access is non-binding and ends automatically after 7 days.

Test it now for free

You may Also be Interested in the Following Articles

News: ICH

ICH: Adoption of the ICH Q1 Stability Guideline

The Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) met on 17-18 November 2026 in Prague, Czechia for its biannual meeting. ICH announced, among other things, adoption of ICH Q1: Stability Testing of Drug Substances and Drug Products as a final harmonised guideline.
Read more
FDA Expands Sampling and Testing of Marketed Medicines

FDA Expands Sampling and Testing of Marketed Medicines

Through its Enhanced Approach for Sampling and Testing (EAST) program, the US Food and Drug Administration combines rapid analytical techniques with established testing methods. The agency aims to test more medicines from US and overseas manufacturers, detect potential quality issues earlier, and use the findings to inform risk-based inspection planning.
Read more
FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
Previous
Next